R Squared Ltd Invests $71,000 in Compugen Ltd. $CGEN

R Squared Ltd purchased a new position in Compugen Ltd. (NASDAQ:CGEN) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 40,008 shares of the biotechnology company’s stock, valued at approximately $71,000.

Several other large investors have also recently modified their holdings of CGEN. US Bancorp DE purchased a new position in shares of Compugen in the 1st quarter worth about $29,000. Calamos Wealth Management LLC purchased a new position in shares of Compugen in the 1st quarter worth about $43,000. Schnieders Capital Management LLC purchased a new position in Compugen in the 1st quarter worth about $131,000. Finally, ARK Investment Management LLC purchased a new position in Compugen in the 1st quarter worth about $1,323,000. Hedge funds and other institutional investors own 12.22% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on CGEN shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Compugen in a research report on Friday. Wall Street Zen lowered Compugen from a “hold” rating to a “sell” rating in a research report on Saturday, August 9th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $4.00.

Compugen Stock Up 7.8%

Compugen stock opened at $1.80 on Monday. The business has a 50-day simple moving average of $1.57 and a two-hundred day simple moving average of $1.54. The company has a market cap of $160.63 million, a P/E ratio of -8.18 and a beta of 2.61. Compugen Ltd. has a 52-week low of $1.13 and a 52-week high of $2.66.

Compugen (NASDAQ:CGEN) last released its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). The firm had revenue of $1.26 million for the quarter, compared to the consensus estimate of $3.95 million. Compugen had a negative net margin of 87.45% and a negative return on equity of 34.77%. Research analysts anticipate that Compugen Ltd. will post -0.03 EPS for the current fiscal year.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.